The positive bioequivalence study is a significant regulatory milestone, but the drug is undisclosed, the ANDA has not been filed, and FDA approval timelines are uncertain. Monitor for the actual ANDA filing, FDA acceptance, and eventual approval decision. The OTC-listed stock may react positively near-term on the catalyst, but fundamental revenue impact is years away.
Price Chart
Executive Summary
Elite Pharmaceuticals reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug. The branded and generic market for this product is $840 million (12 months ending April 2026 per IQVIA). Elite plans to compile data and file an Abbreviated New Drug Application (ANDA) with the FDA, but no timeline for submission or approval was provided.
Key Facts
- Positive pivotal bioequivalence study results for an undisclosed anticonvulsant generic drug
- Branded and generic product sales of $840 million reported by IQVIA for the twelve months ending April 2026
- Elite plans to file an ANDA with the FDA, but no specific timeline for submission or approval was given
- The study was an open-label, randomized, crossover bioequivalence study under fasting conditions
- The exact product is undisclosed, limiting ability to assess competitive landscape or patent/regulatory hurdles
Financial Impact
The addressable market (branded + generic) for this undisclosed anticonvulsant product is $840 million, per IQVIA data cited in the press release.
Risk Factors
- The specific drug product is undisclosed, making it impossible to assess patent, regulatory, or competitive risks
- ANDA filing and FDA approval timelines are unknown and could face delays or rejections
- Elite is a small-cap OTC stock with limited financial resources to commercialize the product if approved
- Forward-looking statements caution that actual results may differ materially
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028610 |
| Exhibit: ex99-1.htm | 0001493152-26-028610 |
| Document: 0001493152-26-028610-index-headers.html | 0001493152-26-028610 |
| Document: 0001493152-26-028610-index.html | 0001493152-26-028610 |
| Document: 0001493152-26-028610.txt | 0001493152-26-028610 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $0.3600 | awaiting T+60 | — | $0.2500 (−30.56%) |
Jun 29, 2026 17w ago | 8-K | $0.3700 $0.2470 | ▼ −33.24% | ▼ −37.08% | $0.2500 (−32.43%) |
Jun 15, 2026 19w ago | 8-K | $0.3700 $0.2599 | ▼ −29.76% | ▼ −31.02% | $0.2500 (−32.43%) |
Jun 1, 2026 21w ago | 8-K | $0.3600 $0.2827 | ▼ −21.47% | ▼ −22.70% | $0.2500 (−30.56%) |
Apr 2, 2026 29w ago | 8-K | $0.3800 $0.3651 | ▼ −3.92% | ▼ −18.08% | $0.2500 (−34.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers